{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-284564","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.242506+00:00","generated_at":"2026-06-21T20:10:13.426331+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acumen Q3 net loss $10.7M; INTERCEPT-AD Phase 1 on track, FDA Fast Track granted","bullets":["Cash, equivalents & marketable securities $200.2M at Sep 30, 2022, sufficient through 2025.","R&D expenses $8.3M (Q3 2022) vs $1.8M (Q3 2021) due to clinical trial ramp.","INTERCEPT-AD enrollment expected to complete Q1 2023; topline data anticipated H2 2023.","FDA granted Fast Track designation for ACU193 in early Alzheimer's in October 2022.","Appointed Derek Meisner as Chief Legal Officer in September 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-284564","json":"https://secwatch.observer/filing/0001193125-22-284564.json","markdown":"https://secwatch.observer/filing/0001193125-22-284564.md","text":"https://secwatch.observer/filing/0001193125-22-284564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/0001193125-22-284564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/d410427d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:10:13.426331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66ef177a4b1c605a1f6f793a718e7bfae15b675f","claim":"Acumen Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income $10.7 million.","evidence_excerpt":"Net loss was $10.7 million for the three-month period ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522284564/0001193125-22-284564-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$10.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}